Chronic kidney disease undergoing hemodialysis poly acrylic acid-poly vinylpyrrolidone, hemodialysis, hemostasis
Conditions
Interventions
Use of poly acrylic acid-poly vinylpyrrolidone for hemostasis after hemodialysis treatment.
Poly acrylic acid-poly vinylpyrrolidone
Sponsors
Yamamoto Suguru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all the inclusion criteria as below, 1. Patients who can obtain written informed consent to participate in this study based on their free will. 2. Patients who are more than 18 years old. 3. Patients undergoing regular hemodialysis treatment 3 times a week and for 3-5 hours each session using internal shunt. 4. Patients who use heparin as anti-coagulant for hemodialysis treatment 5. Patients whose bleeding time after decannulation at the end of hemodialysis treatment is 10 minutes using regular hemostasis pad and band.
Exclusion criteria
Exclusion criteria: Patients who meet any exclusion criteria as below. 1. Patients who participate in other clinical studies. 2. Patients who are pregnant or want pregnancy. 3. Patients who do not use internal shunt as vascular access. 4. Patients who use fingers or use band for more than 10 minutes for hemostasis after decannulation at the end of hemodialysis treatment. 5. Patients who have serious skin disease. 6. Patients who have the plan to start anti-coagulant/anti-platelet therapy 7. Patients that the investigators decide inappropriate to join the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimum hemostasis time at arterial access points | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimum hemostasis time at venous access points The success rate of hemostasis after 11 minute-use of poly acrylic acid-poly vinylpyrrolidone | — |
Contacts
Public ContactSuguru Yamamoto
Niigata University Medical and Dental Hospital
Outcome results
None listed